Cardiocirculatory effects of afterload reduction with oral trimazosin in severe chronic congestive heart failure

Najam A. Awan, John Hermanovich, Charles Whitcomb, Peggy Skinner, Dean T. Mason

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Because improved long-term oral vasodilator therapy for chronic congestive heart failure is needed, the cardiocirculatory effects of the new antihypertensive quinazoline derivative, trimazosin, were evaluated with use of concomitant cardiac catheterization and forearm plethysmography in nine patients with severe chronic congestive heart failure due to coronary disease. After ingestion of 100 to 300 mg (average 172 mg) of trimazosin, the greatly elevated left ventricular filling pressure decreased from 30 to 23 mm Hg and the lowered cardiac index rose from 2.02 to 2.59 liters/min per m2. Considerable improvement in cardiac function occurred within 1 hour after ingestion of trimazosin; peak efficacy was achieved after 2 hours and persisted in the 3rd hour. Heart rate was unchanged and systemic blood pressure was mildly reduced. Because pump performance was enhanced while indexes of myocardial oxygen consumption declined, ventricular efficiency increased. Vascular relaxation was produced in both the systemic resistance and capacitance beds, with venodilation slightly more prominent. This clinical investigation of the acute hemodynamic effects of trimazosin objectively demonstrates that the drug provides considerable hemodynamic benefit in cardiac dysfunction and is therefore a potentially salutary agent for treatment of patients with chronic severe congestive heart failure.

Original languageEnglish (US)
Pages (from-to)126-131
Number of pages6
JournalThe American journal of cardiology
Volume44
Issue number1
DOIs
StatePublished - 1979

Fingerprint

Heart Failure
Eating
Hemodynamics
Quinazolines
Plethysmography
Proxy
Ventricular Pressure
Cardiac Catheterization
Vasodilator Agents
Forearm
Oxygen Consumption
Antihypertensive Agents
Coronary Disease
Blood Vessels
Heart Rate
Blood Pressure
trimazosin
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Cardiocirculatory effects of afterload reduction with oral trimazosin in severe chronic congestive heart failure. / Awan, Najam A.; Hermanovich, John; Whitcomb, Charles; Skinner, Peggy; Mason, Dean T.

In: The American journal of cardiology, Vol. 44, No. 1, 1979, p. 126-131.

Research output: Contribution to journalArticle

Awan, Najam A. ; Hermanovich, John ; Whitcomb, Charles ; Skinner, Peggy ; Mason, Dean T. / Cardiocirculatory effects of afterload reduction with oral trimazosin in severe chronic congestive heart failure. In: The American journal of cardiology. 1979 ; Vol. 44, No. 1. pp. 126-131.
@article{81418b92f115437abe6c2a3828000167,
title = "Cardiocirculatory effects of afterload reduction with oral trimazosin in severe chronic congestive heart failure",
abstract = "Because improved long-term oral vasodilator therapy for chronic congestive heart failure is needed, the cardiocirculatory effects of the new antihypertensive quinazoline derivative, trimazosin, were evaluated with use of concomitant cardiac catheterization and forearm plethysmography in nine patients with severe chronic congestive heart failure due to coronary disease. After ingestion of 100 to 300 mg (average 172 mg) of trimazosin, the greatly elevated left ventricular filling pressure decreased from 30 to 23 mm Hg and the lowered cardiac index rose from 2.02 to 2.59 liters/min per m2. Considerable improvement in cardiac function occurred within 1 hour after ingestion of trimazosin; peak efficacy was achieved after 2 hours and persisted in the 3rd hour. Heart rate was unchanged and systemic blood pressure was mildly reduced. Because pump performance was enhanced while indexes of myocardial oxygen consumption declined, ventricular efficiency increased. Vascular relaxation was produced in both the systemic resistance and capacitance beds, with venodilation slightly more prominent. This clinical investigation of the acute hemodynamic effects of trimazosin objectively demonstrates that the drug provides considerable hemodynamic benefit in cardiac dysfunction and is therefore a potentially salutary agent for treatment of patients with chronic severe congestive heart failure.",
author = "Awan, {Najam A.} and John Hermanovich and Charles Whitcomb and Peggy Skinner and Mason, {Dean T.}",
year = "1979",
doi = "10.1016/0002-9149(79)90261-3",
language = "English (US)",
volume = "44",
pages = "126--131",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Cardiocirculatory effects of afterload reduction with oral trimazosin in severe chronic congestive heart failure

AU - Awan, Najam A.

AU - Hermanovich, John

AU - Whitcomb, Charles

AU - Skinner, Peggy

AU - Mason, Dean T.

PY - 1979

Y1 - 1979

N2 - Because improved long-term oral vasodilator therapy for chronic congestive heart failure is needed, the cardiocirculatory effects of the new antihypertensive quinazoline derivative, trimazosin, were evaluated with use of concomitant cardiac catheterization and forearm plethysmography in nine patients with severe chronic congestive heart failure due to coronary disease. After ingestion of 100 to 300 mg (average 172 mg) of trimazosin, the greatly elevated left ventricular filling pressure decreased from 30 to 23 mm Hg and the lowered cardiac index rose from 2.02 to 2.59 liters/min per m2. Considerable improvement in cardiac function occurred within 1 hour after ingestion of trimazosin; peak efficacy was achieved after 2 hours and persisted in the 3rd hour. Heart rate was unchanged and systemic blood pressure was mildly reduced. Because pump performance was enhanced while indexes of myocardial oxygen consumption declined, ventricular efficiency increased. Vascular relaxation was produced in both the systemic resistance and capacitance beds, with venodilation slightly more prominent. This clinical investigation of the acute hemodynamic effects of trimazosin objectively demonstrates that the drug provides considerable hemodynamic benefit in cardiac dysfunction and is therefore a potentially salutary agent for treatment of patients with chronic severe congestive heart failure.

AB - Because improved long-term oral vasodilator therapy for chronic congestive heart failure is needed, the cardiocirculatory effects of the new antihypertensive quinazoline derivative, trimazosin, were evaluated with use of concomitant cardiac catheterization and forearm plethysmography in nine patients with severe chronic congestive heart failure due to coronary disease. After ingestion of 100 to 300 mg (average 172 mg) of trimazosin, the greatly elevated left ventricular filling pressure decreased from 30 to 23 mm Hg and the lowered cardiac index rose from 2.02 to 2.59 liters/min per m2. Considerable improvement in cardiac function occurred within 1 hour after ingestion of trimazosin; peak efficacy was achieved after 2 hours and persisted in the 3rd hour. Heart rate was unchanged and systemic blood pressure was mildly reduced. Because pump performance was enhanced while indexes of myocardial oxygen consumption declined, ventricular efficiency increased. Vascular relaxation was produced in both the systemic resistance and capacitance beds, with venodilation slightly more prominent. This clinical investigation of the acute hemodynamic effects of trimazosin objectively demonstrates that the drug provides considerable hemodynamic benefit in cardiac dysfunction and is therefore a potentially salutary agent for treatment of patients with chronic severe congestive heart failure.

UR - http://www.scopus.com/inward/record.url?scp=0018751212&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018751212&partnerID=8YFLogxK

U2 - 10.1016/0002-9149(79)90261-3

DO - 10.1016/0002-9149(79)90261-3

M3 - Article

VL - 44

SP - 126

EP - 131

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 1

ER -